Cargando…

Liver diseases in COVID-19: Etiology, treatment and prognosis

In December 2019, a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China causing coronavirus disease-2019 (COVID-19). Numerous studies have shown varying degrees of liver damage in patients infected with SARS-CoV-2. However, in previous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jian, Song, Shu, Cao, Hong-Cui, Li, Lan-Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Opinion Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243650/ https://www.ncbi.nlm.nih.gov/pubmed/32476793 http://dx.doi.org/10.3748/wjg.v26.i19.2286

Ejemplares similares

Insights from nanotechnology in COVID-19 treatment
por: Tang, Zhongmin, et al.
Publicado: (2021)

Sexual dysfunctions and their treatment in liver diseases
por: Jagdish, Rakesh Kumar
Publicado: (2022)

COVID-19 and liver injury in individuals with obesity
por: Lempesis, Ioannis G, et al.
Publicado: (2023)

Post-hypoxic myoclonus: Differentiating benign and malignant etiologies in diagnosis and prognosis
por: Freund, Brin, et al.
Publicado: (2017)

COVID-19 combined with liver injury: Current challenges and management
por: Deng, Man-Ling, et al.
Publicado: (2021)

Amantadine Treatment for People with COVID-19
por: Araújo, Ramiro, et al.
Publicado: (2020)

Microbial metabolites in non-alcoholic fatty liver disease
por: Zhou, Da, et al.
Publicado: (2019)

COVID-19 and the liver: What do we know so far?
por: Nasa, Prashant, et al.
Publicado: (2021)

COVID-19 and the liver: What do we know after six months of the pandemic?
por: Fierro, Nora A.
Publicado: (2020)

Considerations for Home-Based Treatment of Fabry Disease in Poland during the COVID-19 Pandemic and Beyond
por: Nowicki, Michał, et al.
Publicado: (2021)

Fluoroquinolones for the treatment of latent Mycobacterium tuberculosis infection in liver transplantation
por: Silva, Jose Tiago, et al.
Publicado: (2019)

Mechanisms and consequences of COVID-19 associated liver injury: What can we affirm?
por: Brito, Carlos Antunes, et al.
Publicado: (2020)

Quinacrine, an Old Drug with Potentially usefull in the Treatment for COVID-19
por: PINEDA, BENJAMIN
Publicado: (2021)

Going viral? Linking the etiology of human prostate cancer to the PCA3 long noncoding RNA and oncogenic viruses
por: Teixeira, Andre A, et al.
Publicado: (2017)

Uncertainty about the Efficacy of Remdesivir on COVID-19
por: Yoo, Jin-Hong
Publicado: (2020)

Role of monoclonal antibody drugs in the treatment of COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Current status of COVID-19 treatment: An opinion review
por: Di Franco, Sveva, et al.
Publicado: (2020)

Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease
por: Peñaloza, Hernán F., et al.
Publicado: (2021)

Review of inflammatory bowel disease and COVID-19
por: Sultan, Keith, et al.
Publicado: (2020)

Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation
por: Samuel, Didier, et al.
Publicado: (2018)

GK1: An Alternative Treatment to Control the Respiratory Complications During COVID19
por: Fragoso, Gladis, et al.
Publicado: (2021)

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
por: Saha, Abinit, et al.
Publicado: (2020)

S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19
por: Arafah, Azher, et al.
Publicado: (2020)

Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More
por: Saha, Abinit, et al.
Publicado: (2020)

Increased demand for orthodontic treatments during the COVID-19 pandemic: a commentary
por: Omran, Rahaf, et al.
Publicado: (2023)

Using nano-selenium to combat Coronavirus Disease 2019 (COVID-19)?()
por: He, Lina, et al.
Publicado: (2021)

Coronavirus disease 2019 and non-alcoholic fatty liver disease
por: Bellanti, Francesco, et al.
Publicado: (2021)

Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
por: Karampela, Irene, et al.
Publicado: (2020)

Nasal therapy—The missing link in optimising strategies to improve prevention and treatment of COVID-19
por: Ratcliffe, Norman A., et al.
Publicado: (2021)

Fevers: Their History, Etiology, Diagnosis, Prognosis and Treatment
Publicado: (1887)

Secreted Protein Acidic and Rich in Cysteine (SPARC) to Manage Coronavirus Disease-2019 (COVID-19) Pandemic and the Post-COVID-19 Health Crisis
por: Ghanemi, Abdelaziz, et al.
Publicado: (2023)

Coronavirus Disease 2019 (COVID-19) Crisis Measures: Health Protective Properties?
por: Ghanemi, Abdelaziz, et al.
Publicado: (2021)

Epidemic Diseases and Chinese Medicine: Example of SARS and COVID-19: Part Two
por: Dubois, Jean-Claude
Publicado: (2020)

Diabetes and COVID-19: Diseases of racial, social and glucose intolerance
por: Chowdhury, Tahseen A
Publicado: (2021)

The calm after the storm: re-starting ART treatments safely in the wake of the COVID-19 pandemic
por: Gianaroli, Luca, et al.
Publicado: (2020)

Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic
por: Dunlop, Adrian, et al.
Publicado: (2020)

Etiology and management of liver injury in patients with COVID-19
por: Yang, Rui-Xu, et al.
Publicado: (2020)

Correlation of HLA-DP/DQ polymorphisms with transplant etiologies and prognosis in liver transplant recipients
por: Li, Yi, et al.
Publicado: (2017)

PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates
por: Clancy, Cornelius J, et al.
Publicado: (2020)

Effective mitigation strategy in early stage of COVID-19 pandemic in China
por: Yu, Xiao-Yue, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m51204isbugopnjcp7tlngm6tv